Ferring activates first sites in a three-arm study of ADSTILADRIN as a monotherapy or in combination with chemotherapy or an ...

(UroToday.com) The 2024 SUO annual meeting included a session on non muscle invasive bladder cancer, featuring a presentation by Dr. Ashish Kamat discussing BCG unresponsive cancer in 2024.

SUO annual meeting included a session on non muscle invasive bladder cancer (NMIBC), featuring a presentation by Dr. Sima Porten discussing the heterogeneity of intermediate risk NMIBC. Based on the ...

Bladder cancer ranks as the 10th most commonly diagnosed cancer globally, affecting both men and women. Approximately 75% of patients are initially diagnosed with non-muscle invasive bladder cancer ...

UroGen Pharma has reported the outcomes from a long-term follow-up study of JELMYTO for pyelocalyceal solution for treating ...

Rigel Pharmaceuticals, Inc. , a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast ...

Paxton Wiffler, Chief Operating Officer, Monarch Healthcare Management, is the recipient of the 2024 Member of the Year award, presented by Care Providers of Minnesota, a membership association ...

Amphastar Pharmaceuticals (NASDAQ:AMPH – Get Free Report) and UroGen Pharma (NASDAQ:URGN – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two ...

PITTSBURGH, Nov. 12, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: LIPO), a clinical-stage biotechnology company focused on developing innovative therapies for serious diseases with unmet medical needs, today ...

After hours: November 20 at 6:51 p.m. EST ...